These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 36859267)
1. Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial. Zhao Q; Xie R; Zhong W; Liu W; Chen T; Qiu X; Yang L Cost Eff Resour Alloc; 2023 Mar; 21(1):19. PubMed ID: 36859267 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer. Ye ZM; Xu Z; Li H; Li Q Front Public Health; 2023; 11():1046424. PubMed ID: 36844853 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China. Zheng Z; Fang L; Cai H BMC Cancer; 2023 Sep; 23(1):823. PubMed ID: 37667230 [TBL] [Abstract][Full Text] [Related]
4. Comparative Cost-Effectiveness of Gemcitabine and Cisplatin in Combination with S-1, Durvalumab, or Pembrolizumab as First-Line Triple Treatment for Advanced Biliary Tract Cancer. Kashiwa M; Maeda H J Gastrointest Cancer; 2024 Dec; 55(4):1569-1580. PubMed ID: 39172318 [TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor for patients with advanced biliary tract cancer: A cost-effectiveness analysis. Zhu Y; Liu K; Zhu H Liver Int; 2023 Oct; 43(10):2292-2301. PubMed ID: 37592868 [TBL] [Abstract][Full Text] [Related]
6. First-line tremelimumab plus durvalumab and chemotherapy Liu W; Huo G; Chen P Front Pharmacol; 2023; 14():1163381. PubMed ID: 37547328 [No Abstract] [Full Text] [Related]
7. Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status. Liu G; Kang S; Wang X; Shang F Front Oncol; 2021; 11():669195. PubMed ID: 33987103 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China. Zhao Z; Chen T; Zhou Z; Guo R; Liu Q BMJ Open; 2023 Dec; 13(12):e071832. PubMed ID: 38110377 [TBL] [Abstract][Full Text] [Related]
9. A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan. Tsukiyama I; Ejiri M; Yamamoto Y; Nakao H; Yoneda M; Matsuura K; Arakawa I; Saito H; Inoue T J Gastrointest Cancer; 2017 Dec; 48(4):326-332. PubMed ID: 27785685 [TBL] [Abstract][Full Text] [Related]
10. Tremelimumab and durvalumab with chemotherapy in first-line treatment for metastatic non-small cell lung cancer: a US-based cost-effectiveness analysis. Zhao Z; Zeng X; Zhou Z; Liu Q Transl Lung Cancer Res; 2024 Sep; 13(9):2296-2306. PubMed ID: 39430324 [TBL] [Abstract][Full Text] [Related]
11. Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis. Han J; Tian K; Yang J; Gong Y Lung Cancer; 2020 Aug; 146():42-49. PubMed ID: 32512272 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression. Zhang C; Liu Y; Tan J; Tian P; Li W Front Oncol; 2023; 13():1093469. PubMed ID: 36998459 [TBL] [Abstract][Full Text] [Related]
13. First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis. Lin S; Luo S; Gu D; Li M; Rao X; Wang C; Huang P; Xu X; Weng X Oncologist; 2021 Nov; 26(11):e2013-e2020. PubMed ID: 34431578 [TBL] [Abstract][Full Text] [Related]
14. First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis. Liang X; Meng M; Qin S; Chen X; Li Y Sci Rep; 2024 Jun; 14(1):14496. PubMed ID: 38914660 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective. Tong YH; Ding HY; Xin WX; Zhong LK; Xu GQ; Zhang B; Yang GN; Fang L Tumori; 2022 Feb; 108(1):33-39. PubMed ID: 33511911 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China. Wu B; Chen H; Shen J; Ye M Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US. Luo X; Cai T; Wu J; Li X; Wang X; Ma H Front Pharmacol; 2024; 15():1393559. PubMed ID: 39206260 [No Abstract] [Full Text] [Related]
18. Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China. Liu G; Kang S Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):85-91. PubMed ID: 33627014 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China. Lin YT; Zhou CC; Xu K; Zhang MD; Li X Ther Adv Med Oncol; 2023; 15():17588359231213621. PubMed ID: 38028139 [TBL] [Abstract][Full Text] [Related]
20. Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis. Huo G; Liu W; Kang S; Chen P Front Pharmacol; 2023; 14():1131219. PubMed ID: 36865925 [No Abstract] [Full Text] [Related] [Next] [New Search]